For the Inventor, By the Inventor

Enter assignee name

Baxter Aktiengesellschaft

USPTO Granted Patents = 67

CIPO Patents = 4

EPO Patents = 4

Trademarks = 1

Forward Citations = 1,165

Loading Chart...

Loading Chart...

85 inventors (with patents filed for the assignee):

Johann J Eibl (29 out of 101 patents)

Friedrich Dorner (28 out of 91 patents)

Hans-Peter Schwarz (14 out of 105 patents)

4. Peter Turecek (14 out of 118 patents)

5. Bernhard Fischer (10 out of 62 patents)

6. Artur Mitterer (9 out of 53 patents)

7. Uwe Schlokat (9 out of 13 patents)

8. Heinz Redl (7 out of 27 patents)

9. Falko-Guenter Falkner (6 out of 17 patents)

10. Guenther Schlag (6 out of 6 patents)

11. Noel Barrett (5 out of 19 patents)

12. Michele Himmelspach (5 out of 7 patents)

13. Michael Pfleiderer (5 out of 6 patents)

14. Friedrich Scheiflinger (4 out of 76 patents)

15. Wolfgang Mundt (4 out of 63 patents)

Core Competencies:

Plasma Protein Medicament

Fibrinogen-based Tissue Adhesive

Factor IX Antibodies

Recombinant Cell Clones

Von Willebrand Factor

Blood Coagulation Disorders

Hemostatic Sponge

Pathogen Detection Methods

Thrombolytically Active Substances

Influenza Virus Vaccine

Fusion Protein Technology

Biological Sample Purification

67 patents: Sort by Forward Citations

1. 8709492 - Process for producing a plasma protein-containing medicament with reduced concentration of citrate and metals (2014-04-29),

2. 8425947 - Fibrinogen-based tissue adhesive containing an elastase inhibitor (2013-04-23),

3. 7892802 - Fibrinogen-based tissue adhesive containing an elastase inhibitor (2011-02-22),

4. 7459295 - Fibrinogen-based tissue adhesive containing an elastase inhibitor (2008-12-02),

5. 7279161 - Factor IX/factor IXa activating antibodies and antibody derivatives (2007-10-09),

6. 7241603 - Method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method (2007-07-10),

7. 7220569 - Nucleic acids encoding factor X analogues having a modified protease cleavage site (2007-05-22),

8. 7094574 - Recombinant cell clones having increased stability and methods of making and using the same (2006-08-22),

9. 7091325 - Fibrin/fibrinogen-binding conjugate (2006-08-15),

10. 7091015 - Fibrinogen-based tissue adhesive (2006-08-15),

11. 7033590 - Factor IX/factor IXa activating antibodies and antibody derivatives (2006-04-25),

12. 7005502 - Pharmaceutical preparation comprising vWF propeptide (2006-02-28),

13. 6974792 - Alpha 1-antitrypsin preparation as well as a method for producing the same (2005-12-13),

14. 6958322 - Factor X analog with an improved ability to be activated (2005-10-25),

15. 6953837 - Factor VIII/vWF complexes and compositions (2005-10-11),

Baxter Aktiengesellschaft is a global healthcare company that focuses on developing innovative medical solutions. With a mission to save and sustain lives, Baxter provides a wide range of products and services, including pharmaceuticals, medical devices, and biotechnology. Their commitment to improving patient care is evident in their advanced therapies for critical conditions such as hemophilia and immune disorders. Through continuous research and development, Baxter strives to enhance the quality of life for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

67 Patents

#5 in

#63 in Austria

#10,618 in the World

Baxter Aktiengesellschaft

Forward Citations = 1,165

85 inventors:

Johann J Eibl (29 out of 101 patents)

Friedrich Dorner (28 out of 91 patents)

Hans-Peter Schwarz (14 out of 105 patents)

4. Peter Turecek (14 out of 118 patents)

5. Bernhard Fischer (10 out of 62 patents)

Please report any incorrect information to support@idiyas.com

Loading…